Background And Aims The serological responses after severe acute respiratory syndrome
coronavirus 2 vaccination may be attenuated in immunocompromised individuals. The study …

Individuals with Inflammatory Bowel Disease (IBD) are characterized by an increased
vulnerability to complications stemming from infectious diseases. While these patients do not …

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) became a
major concern since the announcement that it is a pandemic in early 2020. Vaccine trials …

The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …

Efficient protection against coronavirus disease 2019 (COVID-19) has been achieved by
immunization with mRNA-based vaccines against severe acute respiratory syndrome …

Patients with immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis
and inflammatory bowel disease, are at increased risk of infection. International guidelines …

Background Some patients with inflammatory bowel disease (IBD) on immunosuppressive
therapies may have a blunted response to certain vaccines, including the messenger RNA …

Introduction There are concerns regarding the effectiveness and safety of SARS‐CoV‐2
vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review and meta …

Patients affected by Inflammatory Bowel Disease (IBD) present higher risk for infection and
suboptimal response upon vaccination. The immunogenicity of SARS-CoV2 vaccination is …

Aim There are limited data on the impact of 2 vs 3 doses of COVID-19 vaccine in patients
with inflammatory bowel disease (IBD). The primary aim of the study was to assess the …